Methylphenidate for Pervasive Developmental Disorders: Safety and Efficacy of Acute Single Dose Test and Ongoing Therapy: An Open-Pilot Study
| العنوان: | Methylphenidate for Pervasive Developmental Disorders: Safety and Efficacy of Acute Single Dose Test and Ongoing Therapy: An Open-Pilot Study |
|---|---|
| المؤلفون: | Adriana Di Martino, Gianluigi Melis, Carlo Cianchetti, Alessandro Zuddas |
| المصدر: | Journal of Child and Adolescent Psychopharmacology. 14:207-218 |
| بيانات النشر: | Mary Ann Liebert Inc, 2004. |
| سنة النشر: | 2004 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Adolescent, MEDLINE, Pilot Projects, behavioral disciplines and activities, Intellectual Disability, mental disorders, medicine, Humans, Pharmacology (medical), Autistic Disorder, Child, Psychiatry, Psychiatric Status Rating Scales, Methylphenidate, Test (assessment), Clinical trial, Psychiatry and Mental health, Attention Deficit Disorder with Hyperactivity, Child Development Disorders, Pervasive, Impulsive Behavior, Pediatrics, Perinatology and Child Health, Psychiatric status rating scales, Central Nervous System Stimulants, Female, Stereotyped Behavior, Psychology, human activities, Clinical psychology, medicine.drug, Autistic symptoms |
| الوصف: | The aim of this study was to investigate the effects of ongoing methylphenidate (MPH) on ADHD-related and autistic symptoms in Pervasive Developmental Disorders (PDD) in children who did not present any adverse effects to an initial acute dose administered at the clinic.Participants included 13 subjects (12 males, with a mean age of 7.9 years) with PDD and moderate to severe hyperactivity/impulsivity. The severity of the symptoms assessment was based on Clinical Global Impression (CGI), Childhood Autism, Child Psychiatric and Conners Parent and Teacher Rating Scales (CPRS). Scores at baseline, and after 1 and 3 months of treatment, were compared to intent-to-treat analyses.One (1) hour after a single MPH dose (0.4 mg/kg), 5 subjects exhibited increased hyperactivity, stereotypes, dysphoria, or motor tics and were rated as minimally or much worse on the CGI Global Improvement Scale. They received no further treatment with MPH. Four (4) of the remaining subjects were rated as improved, and four as unchanged; they proceeded to a 12-week open trial of MPH. Two children remained unchanged: they discontinued treatment after 1 week on maximally tolerated doses. However, in group analyses, behavioral measures of hyperactivity and impulsivity improved significantly, while autism core symptom measures were unaffected. No significant adverse effects were observed in any of the 8 subjects.Administering a single MPH test dose may be useful in identifying children with PDD who may benefit from prolonged therapy. |
| تدمد: | 1557-8992 1044-5463 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5910ef63f082cb8ab46ec5f5e3ba97afTest https://doi.org/10.1089/1044546041649011Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....5910ef63f082cb8ab46ec5f5e3ba97af |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15578992 10445463 |
|---|